{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:01:44Z","timestamp":1784671304008,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["242300420114"],"award-info":[{"award-number":["242300420114"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ202184"],"award-info":[{"award-number":["XYBSKYZZ202184"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ202185"],"award-info":[{"award-number":["XYBSKYZZ202185"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmech.2026.118774","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:22:26Z","timestamp":1773361346000},"page":"118774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of novel napabucasins bearing sulfonylpiperazine scaffolds as potent STAT3 inhibitors for the treatment of prostate cancer"],"prefix":"10.1016","volume":"309","author":[{"given":"Chong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118774_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118774_bib2","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118774_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1586\/14737140.2013.811154","article-title":"Current, new and novel therapy for castration-resistant prostate cancer","volume":"13","author":"Gaya","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.118774_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111922","article-title":"Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"187","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib5","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118774_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/biof.70045","article-title":"The role of STAT3 in cancer: from metabolic regulation to therapeutic targeting","volume":"51","author":"Ashourpour","year":"2025","journal-title":"Biofactors"},{"key":"10.1016\/j.ejmech.2026.118774_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1139\/O09-044","article-title":"Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein","volume":"87","author":"Fletcher","year":"2009","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.ejmech.2026.118774_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118774_bib9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118774_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-10-2694","article-title":"STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers","volume":"17","author":"Morikawa","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118774_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118774_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.118774_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118774_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118774_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189461","article-title":"STAT3 axis in cancer and cancer stem cells: from oncogenesis to targeted therapies","author":"Godugu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.118774_bib16","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110447","article-title":"Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024)","volume":"36","author":"Kang","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118774_bib18","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.2174\/0929867325666180719122729","article-title":"Signal transducer and activator of transcription protein 3 (STAT3): an update on its direct inhibitors as promising anticancer agents","volume":"26","author":"Gelain","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3892\/ijo.2012.1568","article-title":"STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers","volume":"41","author":"Wang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.118774_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118774_bib21","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.3390\/molecules28155678","article-title":"The anticancer effect of napabucasin (BBI608), a natural naphthoquinone","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118774_bib22","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1021\/acs.jnatprod.8b00247","article-title":"Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells","volume":"81","author":"L\u00f6cken","year":"2018","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118774_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","article-title":"Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors","volume":"85","author":"Kawazoe","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118774_bib24","first-page":"263","article-title":"Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial, the lancet","volume":"3","author":"Jonker","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118774_bib25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cam4.675","article-title":"Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2026.118774_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pros.24125","article-title":"Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo","volume":"81","author":"Thulin","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2026.118774_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2018.10.067","article-title":"A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"162","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107955","article-title":"Design, synthesis, and biological evaluation of novel (E)-2-cyano-3-(4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl) derivatives as potent STAT3-targeting anticolorectal cancer agents","volume":"153","author":"Jiang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106541","article-title":"Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors","volume":"136","author":"Zhang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2018.03.054","article-title":"Design, synthesis and activity of BBI608 derivatives targeting on stem cells","volume":"151","author":"Zhou","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118774_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.134971","article-title":"An insight into the biological activity and structure-based drug design attributes of sulfonylpiperazine derivatives","volume":"1278","author":"Kilbile","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.118774_bib32","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","article-title":"Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer, cell death","volume":"25","author":"Froeling","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:16:41Z","timestamp":1784668601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S0223523426002199"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118774","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel napabucasins bearing sulfonylpiperazine scaffolds as potent STAT3 inhibitors for the treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118774"}}